| A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ... New England Journal of Medicine 348 (13), 1201-1214, 2003 | 2153 | 2003 |
| MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia Y Pikman, BH Lee, T Mercher, E McDowell, BL Ebert, M Gozo, A Cuker, ... PLoS medicine 3 (7), e270, 2006 | 1759 | 2006 |
| Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ... Blood, The Journal of the American Society of Hematology 130 (6), 722-731, 2017 | 1459 | 2017 |
| Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia HM Kantarjian, DJ DeAngelo, M Stelljes, G Martinelli, M Liedtke, W Stock, ... New England Journal of Medicine 375 (8), 740-753, 2016 | 1265 | 2016 |
| Differentiation and reversal of malignant changes in colon cancer through PPARγ P Sarraf, E Mueller, D Jones, FJ King, DJ DeAngelo, JB Partridge, ... Nature medicine 4 (9), 1046-1052, 1998 | 1256 | 1998 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1231 | 2013 |
| Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials J Koreth, R Schlenk, KJ Kopecky, S Honda, J Sierra, BJ Djulbegovic, ... Jama 301 (22), 2349-2361, 2009 | 1098 | 2009 |
| Acute myeloid leukemia ontogeny is defined by distinct somatic mutations RC Lindsley, BG Mar, E Mazzola, PV Grauman, S Shareef, SL Allen, ... Blood, The Journal of the American Society of Hematology 125 (9), 1367-1376, 2015 | 969 | 2015 |
| Principios de Medicina Interna Vol. 1 TR Harrison, A Fauci, E Braunwald, K Isselbacher, J Wilson, J Martin McGraw Hill-Interamericana, 1994 | 912 | 1994 |
| Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 RM Stone, DJ DeAngelo, V Klimek, I Galinsky, E Estey, SD Nimer, ... Blood 105 (1), 54-60, 2005 | 846 | 2005 |
| Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia R Pan, LJ Hogdal, JM Benito, D Bucci, L Han, G Borthakur, J Cortes, ... Cancer discovery 4 (3), 362-375, 2014 | 719 | 2014 |
| Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy TN Chonghaile, KA Sarosiek, TT Vo, JA Ryan, A Tammareddi, ... Science 334 (6059), 1129-1133, 2011 | 631 | 2011 |
| Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and … T Fischer, RM Stone, DJ DeAngelo, I Galinsky, E Estey, C Lanza, E Fox, ... Journal of clinical oncology 28 (28), 4339, 2010 | 592 | 2010 |
| Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ... Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018 | 513 | 2018 |
| KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, ... The Lancet 398 (10299), 491-502, 2021 | 420 | 2021 |
| Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia A Yoda, Y Yoda, S Chiaretti, M Bar-Natan, K Mani, SJ Rodig, N West, ... Proceedings of the National Academy of Sciences 107 (1), 252-257, 2010 | 404 | 2010 |
| Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms O Wolach, RS Sellar, K Martinod, D Cherpokova, M McConkey, ... Science translational medicine 10 (436), eaan8292, 2018 | 380 | 2018 |
| Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age EP Alyea, HT Kim, V Ho, C Cutler, J Gribben, DJ DeAngelo, SJ Lee, ... Blood 105 (4), 1810-1814, 2005 | 373 | 2005 |
| Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML TT Vo, J Ryan, R Carrasco, D Neuberg, DJ Rossi, RM Stone, ... Cell 151 (2), 344-355, 2012 | 367 | 2012 |
| Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation M Wadleigh, PG Richardson, D Zahrieh, SJ Lee, C Cutler, V Ho, EP Alyea, ... Blood 102 (5), 1578-1582, 2003 | 366 | 2003 |
